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SUMMARY
Cachexia isawastingsyndromecharacterizedbypro-
nounced skeletal muscle loss. In cancer, cachexia is
associated with increased morbidity and mortality
and decreased treatment tolerance. Although ad-
vances have beenmade in understanding themecha-
nisms of cachexia, translating these advances to the
clinic has been challenging. One reason for this short-
coming may be the current animal models, which fail
to fully recapitulate the etiology of human cancer-
induced tissue wasting. Because pancreatic ductal
adenocarcinoma (PDA)presentswithahigh incidence
of cachexia, we engineered a mouse model of PDA
that we named KPP. KPP mice, similar to PDA pa-
tients, progressively lose skeletal and adipose mass
as a consequence of their tumors. In addition, KPP
muscles exhibit a similar gene ontology as cachectic
patients.Weenvision that theKPPmodelwill beause-
ful resource for advancing our mechanistic under-
standing and ability to treat cancer cachexia.
INTRODUCTION
The defining symptom of cancer cachexia is unintentional weight
loss because of depletion of skeletal muscle. This wasting cannot
be prevented by supplemental nutrition and is often correlated
with increased whole-body inflammation and anorexia (Argile´s
et al., 2014). Cachexia occurs in at least half of all cancer patients
and is associated with advanced disease and palliative care.
However, in gastrointestinal malignancies, especially pancreatic
ductal adenocarcinoma (PDA), cachexia often presents much
earlier, with approximately 70% of PDA patients meeting
cachexia criteria at cancer diagnosis (Fearon et al., 2011; Nemer
et al., 2017).
With a 9% 5-year survival rate and increasing incidence rates,
PDA remains a devastating disease (American Cancer Society,
2018). Although resistance to current therapies and the difficultly
of diagnosing early-stage malignancy are important contributors
to the highmortality rate of PDA patients, the cachexia syndrome
also contributes to poor survival in this disease by lowering pa-
tient tolerance of chemo- and radiotherapy (Andreyev et al.,
1998; Bachmann et al., 2008; Kieler et al., 2017; Moningi et al.,
2015; Pausch et al., 2012; von Haehling et al., 2016). Thus, as
the search continues to more effectively diagnose and treat
PDA, managing cachexia provides an additional strategy to
decrease patient morbidity and mortality.
Despite the clear need to prevent and treat cachexia, thera-
pies are currently lacking, as evidenced by two recent phase III
clinical trials that failed to achieve their primary endpoints (Le-
Rademacher et al., 2017; Temel et al., 2016). Although a number
of factors likely contributed to the failure of these trials, one lim-
itation may be the animal models currently used to study cancer
cachexia. Two commonly used mouse models are xenograft co-
lon-26 (C-26) and Lewis lung carcinoma (LLC) (Acharyya et al.,
2004; Bonetto et al., 2016; He et al., 2013; Judge et al., 2014;
Penna et al., 2010; Talbert et al., 2017; Zhang et al., 2017).
Although these models have been useful for our laboratory and
others in elucidating numerous mechanisms of tissue wasting,
they often come under scrutiny for their inability to fully recapit-
ulate the phenotype of human cancers, either by not forming
spontaneous tumors or because of their inability to reconstitute
a tumor microenvironment. These models are used in a tumor-
agnostic manner and are also quite large, typically representing
more than 10% of the entire body mass (Talbert et al., 2017;
Zhang et al., 2017). They are also aggressive and induce
cachexia on a timescale of only a few weeks (Roberts et al.,
2013a; Talbert et al., 2014, 2017).
In this study, we tested for a disparity between mice and hu-
mans by comparing global gene expression changes in skeletal
muscles from C-26 and LLC-bearing mice compared with bi-
opsies obtained from PDA patients with cachexia. The results
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revealed little overlap in both the number and classification of
genes expressed, emphasizing that, on the molecular level,
these models may not be the most appropriate to study human
cachexia. In addition to these xenograft models, the classic
genetically engineered mouse model (GEMM) of PDA, called
the Kras; p53; Cre (KPC) mouse, is gaining attraction in cachexia
studies. However, as we reveal, this model also has limitations
that question its usefulness to study cachexia. Such findings
prompted us to design a mouse model of PDA to better reflect
the features of human cancer-induced wasting.
RESULTS
The C-26 and LLC Models Do Not Resemble the Muscle
Gene Expression Signature of PDA Patients
To assess the ability of the C-26 and LLC models to reflect PDA-
inducedcachexia,wecompareddifferencesbetweencontrol and
cachectic transcriptional profiles determined byRNA sequencing
(RNA-seq) with differences between cachectic pancreatic cancer
Figure 1. Comparing Xenograft Models with
Cachectic Pancreatic Cancer Patients
(A) RNA-seq of tibialis anterior (TA) muscle from
C-26 and LLC tumor-bearing mice (n = 2 males per
group).
(B) RNA-seq of n = 5 male non-cancer patients and
5 male cachectic PDA patients.
(C–F) Gene expression of (C) Atrogin-1, (D) MuRF1,
(E) Atg5, and (F) Bnip3 (n = 8 males for C-26; n = 6
males for LLC; n = 11 controls, 17 cachectic pa-
tients, approximately equal male and female).
Patient characteristics for RNA-seq can be found in
Table S2, and patient characteristics for RT-
PCR can be found in Table S3. Bars represent
mean ± SEM. Closed circles represent individual
data points. *p < 0.05 in a t test.
See Figure S1 for additional information.
patients and control patients. In the C-26
model, using a false discovery rate (FDR)
of < 0.05, we identified 3,474 differentially
expressed genes (DEGs) between control
and cachectic muscles (Figure 1A;
Table S1), which is consistent with pub-
lished microarray data (Bonetto et al.,
2011; Cornwell et al., 2014; Judge et al.,
2014). For the LLC model, we identified
788 DEGs (Figure 1A; Table S1), again
within the range of published data (Black-
well et al., 2018). Although the LLC model
demonstrated fewer DEGs than C-26
mice, gene ontology analysis showed
that DEGs from both models were gener-
ally associated with processes of RNA
translation (Figure S1A). Interestingly,
when similar gene expression profiling
was performed with cachectic PDA pa-
tients, only 141 DEGs were identified
compared with weight-stable patients
without cancer (Figure 1B; Table S1). Although these DEGs
were too few to associate with a biological process by gene
ontology, all five cellular components that associated with these
DEGs involved the extracellular matrix (Figure S1B).
A striking feature of these results was that more than 95% of
the DEGs from human muscle were decreased in cachectic pa-
tients, which we confirmed by qRT-PCR (Figure S1C); this is
consistent with previous findings in cachectic patients with up-
per gastrointestinal (GI) malignancies (Gallagher et al., 2012).
This gene expression pattern stands in stark contrast to the
overwhelming upregulation of genes seen in the C-26 model
(80% upregulated) or the approximately equal proportions of up-
regulated and downregulated DEGs observed in LLC tumor-
bearing mice.
These results suggested that the gene signatures in muscle
from the standard C-26 and LLC models of cancer cachexia
are distinct from that of muscle from cachectic pancreatic can-
cer patients. To test for a discordance specifically in relation to
muscle atrophy, we measured the expression of genes coding
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for components of the ubiquitin proteasome and autophagy
systems, which are considered to be causative in cancer-
induced muscle wasting (Tisdale, 2009). The results showed
the typical large increase in expression of the E3 ubiquitin
ligases MuRF1 and Atrogin-1 in C-26 and LLC models, whereas
no changes in the expression of these genes were seen in mus-
cles from cachectic PDA patients (Figures 1C and 1D). Expres-
sion of the autophagy genes Atg5 and Bnip3 was also increased
in muscle from C-26 and LLC mice but remained unchanged in
cachectic PDA patients (Figures 1E and 1F). A similar lack of
transcriptional changes in these genes in cachectic patients
has been reported by other groups (Bonetto et al., 2013; D’Or-
lando et al., 2014). Collectively, we conclude from these data
that xenograft C-26 and LLC models are not optimal to recapit-
ulate the muscle wasting phenotype of human cancer-induced
cachexia.
KPC Mice Exhibit Variability and Tissue Mass Changes
that Do Not Correlate with Pancreatic Cancer
Progression
Next we tested the established KPC GEMM of PDA (Hingorani
et al., 2005), which has recently been described as a model of
Figure 2. The KPC Mouse as a Model of
Cancer Cachexia
(A–C) KPC mice that have reached endpoint
criteria have lower body weights (A; n = 11), muscle
weights (B; n = 11), and gonadal white adipose
tissue masses (C; n = 5) than littermate control
mice.
(D–F) However, when pancreatic histopathology is
considered (D), mice with mPanIN lesions (n = 4),
early PDA (n = 4), and advanced PDA (n = 3) all
tend to have lower body weights (E) and muscle
weights (F).
Bars represent mean ± SEM. Closed circles
represent individual data points. *p < 0.05 in a
paired t test on absolute weights. Scale bars,
50 mm.
See Figure S2 for additional information.
cachexia (Parajuli et al., 2018; Petruzzelli
et al., 2014; Roberts et al., 2013b). KPC
mice utilize the Pdx1 promoter to drive
Cre recombinase to express mutant
KrasG12D as well as either a floxed or a
lox-stop-lox (LSL) mutant allele of Trp53,
leading mice to a median survival of
approximately 150 days (Figure S2A; Hin-
gorani et al., 2005; Shakya et al., 2013).
Consistent with previous reports, we too
observed that KPC mice (Kras+/LSL-G12D,
Trp53+/R270H, Pdx1+/Cre) that reached
endpoint criteria weighed significantly
less than their littermate controls (Figures
2A and S2B). This reduction in weight
correlated with reduced hindlimb muscle
(tibialis anterior [TA], quadriceps [QUAD],
and gastrocnemius [GAST]) mass and
lower white adipose tissue mass (Figures 2B, S2C, and 2C).
However, when correlating body weight and muscle wasting
with pancreas pathology, we were surprised to find that KPC
mice tended to be smaller than their littermate control mice
regardless of the severity of their pancreatic disease (Figure 2D,
2E, and S2D). In fact, some KPCmice with non-invasive pancre-
atic lesions (referred to as mPanIN) were among the smallest
mice compared with their littermates, whereas other mice with
advanced PDA were of similar weight as their littermate controls
(Figure S2E). Similarly, KPC mice tended to have smaller muscle
mass regardless of pancreas pathology (Figure 2F). Consistent
with the heterogeneity of the model, an RNA-seq analysis of
muscle from KPC mice similar to the one performed for the C-
26 and LLC models returned only a single DEG (FDR < 0.05; Ta-
ble S1). These results are not in keeping with PDA patients,
where lower body and peripheral tissue masses are associated
with cancer.
Generation of the KPP Mouse
Given the limitations we identified in both xenograft models and
KPC mice, we turned our efforts to generating another model
of cancer-induced wasting. When developing this model, we
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considered several aspects reflective of human disease. First,
we sought to model PDA because this disease has among the
highest incidences and severities of cancer cachexia (Baracos
et al., 2018). Next, because PDA develops in adults, we wanted
to induce cancer in postnatal mice. Further, we sought to
achieve a direct association between the development of PDA
and an ensuing cachexia condition. Specifically, because pa-
tients with PDA-induced cachexia lose existing muscle and fat,
we sought to model true tissue wasting as opposed to a condi-
tion of ‘‘perceived wasting,’’ where tissues do not gain mass
because they fail to develop. Finally, we wanted a model that
developed cachexia on a slower timescale than the rapid
wasting that occurs in current xenograft models.
To meet these criteria, we started with the same LSL-KrasG12D
mutant allele found in the KPC mouse but removed the stop
cassette with a tamoxifen-inducible Cre recombinase driven by
the Ptf1a promoter, also known as p48, which remains active
into adulthood in the pancreas (Pan et al., 2013). Our model
also used two floxed alleles of the tumor suppressor Pten that
were inactivated at the same time mutant Kras was induced
(Stanger et al., 2005; Ying et al., 2011). Over 70% of human
pancreatic tumors demonstrate reduced Pten protein expres-
Figure 3. Generation of the KPP Mouse and
Endpoint Analysis
(A) The alleles of the KPP mouse.
(B) Naive Ptfa1ER-Cre/+;Rosa26Tomato+/ mice
express background fluorescence in pancreas
sections, whereas pancreata of tamoxifen-treated
Ptfa1ER-Cre/+;Rosa26Tomato+/mice exhibit a high
fluorescence signal.
(C) KPP mice induced with tamoxifen between 24
and 28 days of age had an average survival of
107 days of age (n = 12). Ticks on the control line
indicate points when a control mouse was eutha-
nized for comparison with a littermate KPP mouse.
Control genotypes include Kras+/+, Ptf1a+/ER-Cre,
Ptenf/f (n = 6), Kras+/+, Ptf1a+/ER-Cre, Pten+/f (n = 1),
Kras+/+, Ptf1a+/ER-Cre, Pten+/+ (n = 1), Kras+/G12D,
Ptf1a+/+, Ptenf/f (n = 1), andKras+/+, Ptf1a+/+, Pten+/f
(n = 3). Control genotypes are presented with their
paired KPP mouse in Table S4.
(D) Endpoint KPP mice demonstrate moderately
well-differentiated to well-differentiated PDA as
evidenced by H&E, Alcian blue, CK19, Ki67, and
a-smooth muscle actin (a-SMA) staining. Scale
bar, 50 mm.
See Figure S3 for additional information.
sion, making Pten deletion relevant to
pancreatic cancer patients (Jiang et al.,
2014; Ying et al., 2011). Together, these
mice exhibit the genotype Kras+/G12D,
Ptf1a+/ER-Cre, Ptenf/f (Figure 3A), which
we named KPP.
We first confirmed that the Ptf1aER-Cre
promoter is active only in the presence
of tamoxifen by breeding Ptf1a+/ER-Cre
mice to Rosa26-tdTomato reporter mice
(Madisen et al., 2010). Mice treated with
five consecutive injections of tamoxifen expressed Tomato in
acinar cells throughout the pancreas, whereas Tomato expres-
sion was not present in Ptf1a+/ER-Cre mice not treated with
tamoxifen (Figure 3B). To initiate tumorigenesis, KPP mice
were injected with tamoxifen between 24 and 28 days of age.
At this age, there was no difference in body mass between con-
trol and KPP mice (Figure S3A). With 100% penetrance, KPP
mice reached endpoint criteria (ascites, weight loss, and leth-
argy) at a median age of 107 days (Figure 3C). In comparison,
all control mice showed no obvious phenotype at this age (geno-
types for each control mouse can be found in Table S4). At
the endpoint, the weights of KPP pancreata were significantly
increased compared with littermate controls, consistent with
tumor burden (Figure S3B). Histological analysis demonstrated
well-differentiated to moderately well-differentiated ductal ade-
nocarcinomas composed of anastomosing and branching
glands lined by mucinous epithelium accompanied by abundant
fibrous stromata. The pancreatic parenchyma was extensively
replaced by the neoplasms (Figure 3D; Figure S3C). Cystic
glands with intraluminal papillary projections were often noted.
Expression of cytokeratin 19 (CK19) demonstrated the ductal
phenotype of the glandular epithelium, and Alcian blue staining
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confirmed the presence of mucin. Additional staining for Ki-67
and a-smooth muscle actin revealed epithelial and stromal pro-
liferative activity and the presence of large numbers of stromal
myofibroblasts, respectively (Figure 3D; Figure S3C; Aichler
et al., 2012).
KPP Mice Exhibit a Cachectic Phenotype
We next sought to evaluate whether KPP mice suffered from
cachexia. KPP mice at their endpoint exhibited decreased
body weight compared with their littermate controls (Figure 4A;
Figure S4A) but, importantly, had similar tibia lengths (Fig-
ure 4B), suggesting that the lower body weights of KPP mice
were not due to a failure to grow. KPP mice also exhibited
decreased TA, QUAD, and GAST muscle masses (Figure 4C).
In the GAST, this decrease in muscle weight was primarily
due to decreased cross-sectional area (CSA) of type IIB or
IIX muscle fibers (Figure 4D). KPP muscle also showed a trend
toward reduced type IIA fiber size (p = 0.06), whereas type I
fibers were spared, which is consistent with other mouse
models of cancer cachexia (Acharyya et al., 2004; Roberts
et al., 2013a). Functionally, muscles from KPP mice exhibited
a decrease in total muscle force production at higher stimula-
tion frequencies, but specific force was not altered (Figure 4E),
suggesting that the sarcomere structure was intact. Consistent
with this phenotype, the content of sarcomeric proteins actin
and myosin per mass of muscle was unchanged in KPP mice
(Figure S4B), which is unlike what we and others have reported
in xenograft cachexia models (Acharyya et al., 2004; Bonetto
et al., 2011) but in line with reports suggesting that sarcomeric
protein content and specific force are maintained in muscles
from cachectic cancer patients (Toth et al., 2013; Weber
et al., 2009). Further, night cage activity was decreased, indi-
cating that KPP mice exhibit reduced whole-body function
(Figure 4F).
In addition to reduced muscle mass and function, endpoint
KPP mice had enlarged spleens (Figure S4C), which is a feature
of both PDA and cachexia (Bonetto et al., 2016; Michaelis et al.,
2017; Talbert et al., 2014). Furthermore, KPP mice had signifi-
cantly lower heart masses (Figure 4G), which is also associated
with many models of cancer cachexia (Bonetto et al., 2016; Mi-
chaelis et al., 2017; Talbert et al., 2014). KPP mice also had
pronouncedly lower white and brown adipose tissue masses
(Figure 4H). Consistent with depleted adipose tissue stores,
KPP mice displayed an increased resting respiratory exchange
ratio (RER), indicative of greater utilization of carbohydrate fuel
stores (Figure 4I). Finally, KPP mice consumed less oxygen
during dark hours (Figure 4J), which may suggest that carbohy-
drate utilization is increased or may simply reflect differences in
activity (Figure 4F).
To ensure that these cachectic phenotypes were not limited to
young mice, where tumor induction was initiated between 3 and
4 weeks of age, we attempted to mimic human PDA in older
adults by injecting tamoxifen in 1-year-old KPP mice. Impor-
tantly, uninjected KPP mice showed no apparent pancreas
pathology, confirming tight regulation of the Ptf1aER-Cre allele
(Figure S4D). In contrast, 1-year-old KPP mice developed PDA
with a median post-tumor initiation survival of 158 days (Figures
S4D–S4F) and exhibited weight loss with associated lower
masses of skeletal, cardiac, and adipose tissues (Figures S4G–
S4J). Thus, induced cachexia occurs in adult KPP mice.
KPP Mice Undergo Progressive Wasting
Although patients can exhibit cachexia throughout the course
of their disease, the incidence of cachexia tends to increase
as the disease progresses (Dewys et al., 1980). To determine
whether KPP mice exhibited progressive wasting, we induced
tumorigenesis at 24–28 days of age and then euthanized
cohorts of mice at 60, 75, and 90 days of age during dis-
ease progression, as evidenced by tumor burden (Fig-
ure S5A). The extent to which the pancreatic parenchyma of
KPP mice was replaced by proliferating ductal profiles and
accompanying stromal fibrosis increased remarkably with age
(Figure 5A). Acinar-to-ductal metaplasia, pancreatic intraepi-
thelial neoplasia (mPanIN), and cystic papillary neoplasms,
all of which constitute non-invasive lesions, and occasional
focally invasive (early carcinoma) lesions were predominant at
60 and 75 days. Notably, large areas of the exocrine and endo-
crine pancreas remained unaffected. In contrast, significantly
larger portions of the pancreatic parenchyma were replaced
by both non-invasive and invasive (advanced carcinoma)
lesions at later time points, with severe parenchymal atrophy
at 90 days and virtually no remaining histologically normal
pancreas by the endpoint.
Although tibia length was not different between control and
KPP mice across all time points (Figure S5B), KPP mice ex-
hibited a progressive decline in body weight compared with their
littermate controls (Figure 5B). Significantly, this decrease in
weight matched a progressive decline in skeletal muscle (TA,
QUAD, and GAST; Figure 5C), heart (Figure 5D), and adipose
mass relative to controls (Figure 5E). In both male and female
KPP mice, the decline in both absolute skeletal muscle began
between days 75 and 90 (Figure S5C), showing that KPP mice
exhibit progressive PDA-induced tissue loss, reflective of the
human disease. Although KPP mice clearly lose existing adi-
pose tissue, 60-day KPP mice tend to have less adipose tissue
than their controls, suggesting that KPP mice may not put on
adipose tissue as effectively as control mice during development
(Figure S5D).
Cachectic Muscle from KPP Mice and PDA Patients
Exhibits a Similar Gene Ontology
Finally, we compared transcriptional profiles between KPP
mice and PDA patients with cachexia (Figures 6A and 6B). In
sharp contrast to our findings with the C-26 and LLC xenograft
models, only 172 DEGs were identified in KPP mice using
an FDR of < 0.05. However, the five most significant biological
process categories identified by gene ontology were related to
the extracellular matrix, reminiscent of the cellular component
gene ontology of cachectic PDA patients (Figure S6A). Further-
more, KPP mice exhibited smaller increases in the expression
of E3 ubiquitin ligase and autophagy genes compared with
the common xenograft models (Figures 6C–6F), and these
modest increases only occurred during end-stage cachexia
(Figure S6B). Together, these results imply that the cachexia
phenotype of KPP mice may more closely resemble that of
PDA patients.
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Figure 4. The KPP Mouse Develops Cachexia
(A and B) KPP mice are smaller than their littermate controls when reaching endpoint criteria (A) but have similar tibia lengths (B).
(C) KPP mice exhibit reduced TA, quadriceps (QUAD), and gastrocnemius (GAST) muscle masses.
(D) Muscle wasting in KPP GAST is associated with lower type IIB or IIX fiber cross-sectional area, whereas type IIA fibers tended to be smaller (p = 0.06).
(E) Absolute ex vivo extensor digitorum longus (EDL) muscle force was significantly reduced at higher stimulation frequencies, but specific force was not altered.
(F) Endpoint KPP mice demonstrate decreased night (awake) activity counts, indicative of depressed whole-body function.
(G and H) KPP mice demonstrate decreased heart weight (G) and decreased masses of gonadal white and subscapular brown adipose (H).
(I) Consistent with decreased adipose tissue stores, KPP mice exhibit an increased daytime respiratory exchange ratio (RER).
(J) KPP mice exhibited decreased night oxygen consumption (VO2).
Bars represent mean ± SEM. Closed circles represent individual data points. *p < 0.05 in a paired t test. n = 12 per group; for cross-sectional area and metabolic
data, n = 5 per group, and formuscle functiondata, n = 3 per group. Evenwhen expressed aspercent controls, statistical testswere conducted on absoluteweights.
See Figure S4 for additional information.
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DISCUSSION
Because mechanistic studies of cancer cachexia are difficult to
complete in human patients, our current knowledge of mecha-
nisms of cancer-induced wasting derives mainly from animal
models of the disease. However, our work presented here sug-
gests that, in many ways, two of the most commonly used xeno-
graft mouse models of cachexia do not reflect gene expression
changes seen in muscle of cachectic PDA patients. This is
perhaps not surprising because both the C-26 and LLC models
result in aggressive tumors and induce rapid wasting over an
approximately 1- to 2-week period (Acharyya et al., 2004,
2005; He et al., 2013; Talbert et al., 2014, 2017; Zhang et al.,
2017). In addition, the loss of skeletal muscle and adipose
mass in these models is generally dependent on inflammatory
factors whose concentration in the circulation far exceeds levels
recorded in cachectic patients (Lerner et al., 2015, 2016a,
2016b; Llovera et al., 1998b; Strassmann et al., 1992; Talbert
et al., 2018).
In an effort to better model the cachexia experienced by
patients, a number of laboratories have recently published
new mouse models of cancer cachexia, often utilizing more
relevant cachexia-inducing cancers, with PDA being the most
common. The three main approaches of these models have
Figure 5. KPP Mice Exhibit Progressive
Cachexia Associated with Advancing
Pancreas Pathology
(A) Pancreatic disease in KPP mice progresses
across their lifespan.
(B–E) Additionally, compared with their littermate
controls, KPPmice progressively lose body weight
(B), skeletal muscle (C), heart mass (D), and white
and brown adipose tissue (E).
Bars represent mean ± SEM. Closed circles
represent individual data points. ‘‘Endpoint’’ KPP
mice have reached Institutional Animal Care and
Use Committee (IACUC) euthanasia criteria and
are the same mice as shown in Figures 3 and 4
(n = 12). n = 5–6 mice per group for the 60-, 75-,
and 90-day time points. Genotypes for each con-
trol mouse can be found in Table S6. *p < 0.05 in a
paired t test on absolute weights. Scale bar, 50 mm.
See Figure S5 for additional information.
been (1) intraperitoneal injections of PDA
cells, which localize to the pancreas;
(2) orthotopic models of PDA in which
cancer cells are injected directly into the
pancreas; and (3) patient-derived xeno-
graft (PDX) models in which a portion of
a resected human pancreatic tumor is
surgically attached to a mouse pancreas
(Delitto et al., 2017; Go et al., 2017; Greco
et al., 2015; Michaelis et al., 2017).
Although these models have the advan-
tage of establishing tumors within the
pancreas, some are limited by their nar-
row window of wasting, similar to the
C-26 and LLC models (Greco et al., 2015; Michaelis et al.,
2017; Yang et al., 2019). Additionally, it is possible that the
post-surgical inflammatory environment created by orthotopic
injections and surgical tumor implantation contributes to the
appearance of wasting rather than deriving from bona fide, tu-
mor-induced tissue loss. Finally, use of human tumors or tumor
cells necessitates the use of immunocompromised mice, which
themselves may fall short in reconstituting the immune profile of
cachexia. Thus, although these models may be an improvement
over the C-26 or LLC models, they still face challenges in repli-
cating human cancer cachexia.
Although a growing number of reports describe KPCmice as a
model of cancer cachexia, in our view, this model also has signif-
icant limitations. Although human PDA is estimated to develop
over the course of at least a decade (Yachida et al., 2010), no ev-
idence suggests that mutant Kras is active prior to birth, as in the
KPCmouse (Guz et al., 1995). Because neonatal skeletal muscle
quadruples in size during the first 3 weeks of life (White et al.,
2010), this raises the suspicion that prenatal activation of an
oncogene might affect the development of skeletal muscle.
This notion is supported by our findings that KPC mice tend to
be smaller than their littermate controls regardless of pancreas
pathology. An additional consideration with the use of KPC
mice as a cachexia model is the propensity of these mice to
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develop other tumors outside of the pancreas (Gades et al.,
2008; Lampson et al., 2012), which might influence how
cachexia is interpreted. Admittedly, it may be possible to reduce
the incidence of non-pancreas tumors by backcrossing mice
into a pure strain, but this remains to be tested. Finally, we spec-
ulate that performing pre-clinical cachexia studies would be
challenging in the KPC model because the slope of the survival
curve of these mice is gradual (Hingorani et al., 2005; Shakya
et al., 2013), meaning large cohorts would likely be required to
achieve sufficient power to assess the effectiveness of an anti-
cachexia compound.
For our purposes, we sought to use a GEMMof PDA that could
overcome some of the shortcomings of the current models. Our
findings show that theKPPmouse is suitable as amodel of cancer
cachexia for several reasons. The inducible nature of the Cre re-
combinase utilized in the KPP mouse allows PDA and its associ-
ated cachexia to be induced after the rapid neonatal growth of
mice has concluded. This allowed us to better model the actual
loss of muscle and adipose tissue in patients with PDA, as
opposed to potentially slowing development and giving the
appearance of cachexia. We also showed that the inducible Cre
Figure 6. The Gene Ontology of KPP Mice
Resembles that of Cachectic PDA Patients
(A) RNA-seq of TA muscle from KPP mice (n = 2
males per group).
(B) RNA-seq of n = 5male non-cancer patients and
5 male cachectic PDA patients.
(C–F) Gene expression of (C) Atrogin-1, (D) MuRF1,
(E) Atg5, and (F) Bnip3 (n = 8 males for C-26; n = 6
males for LLC, n = 3 males and 3 females for KPP;
n = 11 controls, 17 cachectic patients, approxi-
mately equal male and female).
Patient characteristics for RNA-seq can be found
in Table S2, and patient characteristics for RT-
PCR can be found in Table S3. Bars represent
mean ± SEM. Closed circles represent individual
data points. *p < 0.05 in a t test.
See Figure S6 for additional information.
is amenable to inducing tumor develop-
ment inoldermice,whichallowsmanipula-
tion of experimental conditions associated
with PDA in older adults. Moreover, the
slope of the survival curve of KPP mice is
steeper than that of KPCmice (FigureS6C;
Hingorani et al., 2005; Shakya et al.,
2013), improving the feasibility of testing
potential anti-cachexia compounds.
Althoughtumor-inducedmusclewasting
in KPP mice appears to more closely
model the cachexia seen in PDA patients,
this model is not without limitations.
Because KPP mice lose normal pancre-
atic parenchyma, we cannot exclude
the possibility, as reported recently (Danai
et al., 2018), that pancreatic exocrine
insufficiencycontributes to tumor-induced
wasting in thismodel. Further, it is possible
that features of KPPmice are selective toPDAand, thus, less use-
ful to study other tumor types that also promote cachexia. Despite
these limitations,weview theKPPmouseasan improvementover
existing animal models of cachexia and anticipate that KPP mice
will prove to be a useful tool in improving our understanding of
the mechanisms driving tissue wasting and in translating that
understanding into new anti-cachexia therapies.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d LEAD CONTACT AND MATERIALS AVAILABILITY
d EXPERIMENTAL MODEL AND SUBJECT DETAILS
B Animals
B Human Subjects
d METHOD DETAILS
B RNA-Seq and Gene Ontology
B Real-Time RT-PCR
Cell Reports 28, 1612–1622, August 6, 2019 1619
B Pancreas Histopathology
B CLAMS
B Muscle Fiber Size Measurements
B Muscle Function Measurements
B Sarcomeric Protein Analysis
d QUANTIFICATION AND STATISTICAL ANALYSIS
d DATA AND CODE AVAILABILITY
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.
celrep.2019.07.016.
ACKNOWLEDGMENTS
The authors would like to thank David Wang and Nivedita Ratman for thought-
ful discussions of the manuscript, Lisa Baer for assistance with CLAMS; Tom
Liu for assistance with the RNA-seq; Sabahattin Bicer for assistance with the
myofilament gels; Jason Bice, Daphne Bryant, Raleigh Kladeny, and Melodie
Parrish for histology assistance; Ericka Haverick, Karina Woodward, Angela
Sarna, and EricaWilliams for coordination of human subjects; and Jeffrey Cha-
kedis, Heather Lewis, andMitchell Ramsey for clinical data extraction. Funding
was provided by NIH R21AR071021 (to D.C.G.), R01CA180057 (to D.C.G.),
and K99AR071508 (to E.E.T.); and American Cancer Society postdoctoral
fellowship PF-15-156-01-CSM (to E.E.T.) and a Weiss postdoctoral fellowship
(to E.E.T.). Additional support was from The Ohio State Comprehensive Can-
cer Center P30CA016058, OSUCCC institutional funds and Hollings Cancer
Center P30CA138313. A portion of this work was conducted in a facility con-
structed with support from NIH C06 RR015455.
AUTHOR CONTRIBUTIONS
Conceptualization, E.E.T. and D.C.G.; Formal Analysis, E.E.T., M.C.C., and
A.W.; Investigation E.E.T., M.C.C., K.J.L., P.V.R., M.S., B.P., and P.J.R.; Re-
sources, R.S., D.S.E., D.C.E., M.E.D., and C.R.S.; Data Curation, E.E.T. and
P.V.R.; Writing–Original Draft, E.E.T. and D.C.G.; Writing–Review & Editing,
E.E.T., M.C.C., K.J.L., P.V.R., M.S., R.S., G.W.L., M.C.O., B.P., N.W., P.J.R.,
A.W., C.D.T, D.S.E., D.C.E., M.E.D., C.R.S., and D.C.G.; Visualization, E.E.T.
and D.C.G., Supervision E.E.T., G.W.L., M.C.O., N.W., C.D.T., and D.C.G.;
Funding Acquisition, E.E.T. and D.C.G.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: November 1, 2018
Revised: January 24, 2019
Accepted: July 3, 2019
Published: August 6, 2019
REFERENCES
Acharyya, S., Ladner, K.J., Nelsen, L.L., Damrauer, J., Reiser, P.J., Swoap, S.,
and Guttridge, D.C. (2004). Cancer cachexia is regulated by selective targeting
of skeletal muscle gene products. J. Clin. Invest. 114, 370–378.
Acharyya, S., Butchbach, M.E., Sahenk, Z., Wang, H., Saji, M., Carathers, M.,
Ringel, M.D., Skipworth, R.J., Fearon, K.C., Hollingsworth, M.A., et al. (2005).
Dystrophin glycoprotein complex dysfunction: a regulatory link between
muscular dystrophy and cancer cachexia. Cancer Cell 8, 421–432.
Aichler, M., Seiler, C., Tost, M., Siveke, J., Mazur, P.K., Da Silva-Buttkus, P.,
Bartsch, D.K., Langer, P., Chiblak, S., D€urr, A., et al. (2012). Origin of pancre-
atic ductal adenocarcinoma from atypical flat lesions: a comparative study in
transgenic mice and human tissues. J. Pathol. 226, 723–734.
American Cancer Society (2018). Cancer Facts & Figures 2018 (American Can-
cer Society).
Andreyev, H.J., Norman, A.R., Oates, J., and Cunningham, D. (1998). Why do
patients with weight loss have a worse outcome when undergoing chemo-
therapy for gastrointestinal malignancies? Eur. J. Cancer 34, 503–509.
Argile´s, J.M., Busquets, S., Stemmler, B., and Lo´pez-Soriano, F.J. (2014).
Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer 14,
754–762.
Bachmann, J., Heiligensetzer, M., Krakowski-Roosen, H., Buchler, M.W., Fri-
ess, H., and Martignoni, M.E. (2008). Cachexia worsens prognosis in patients
with resectable pancreatic cancer. J. Gastrointest. Surg. 12, 1193–1201.
Baracos, V.E., Martin, L., Korc, M., Guttridge, D.C., and Fearon, K.C.H. (2018).
Cancer-associated cachexia. Nat. Rev. Dis. Primers 4, 17105.
Blackwell, T.A., Cervenka, I., Khatri, B., Brown, J.L., Rosa-Caldwell, M.E., Lee,
D.E., Perry, R.A., Jr., Brown, L.A., Haynie, W.S., Wiggs, M.P., et al. (2018).
Transcriptomic analysis of the development of skeletal muscle atrophy in
cancer-cachexia in tumor-bearing mice. Physiol. Genomics 50, 1071–1082.
Blough, E.R., Rennie, E.R., Zhang, F., and Reiser, P.J. (1996). Enhanced elec-
trophoretic separation and resolution of myosin heavy chains in mammalian
and avian skeletal muscles. Anal. Biochem. 233, 31–35.
Bonetto, A., Aydogdu, T., Kunzevitzky, N., Guttridge, D.C., Khuri, S., Koniaris,
L.G., and Zimmers, T.A. (2011). STAT3 activation in skeletal muscle links mus-
cle wasting and the acute phase response in cancer cachexia. PLoS ONE 6,
e22538.
Bonetto, A., Penna, F., Aversa, Z., Mercantini, P., Baccino, F.M., Costelli, P.,
Ziparo, V., Lucia, S., Rossi Fanelli, F., andMuscaritoli, M. (2013). Early changes
of muscle insulin-like growth factor-1 andmyostatin gene expression in gastric
cancer patients. Muscle Nerve 48, 387–392.
Bonetto, A., Rupert, J.E., Barreto, R., and Zimmers, T.A. (2016). The Colon-26
Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer
Cachexia. J. Vis. Exp. Published online November 30, 2016. https://doi.org/
10.3791/54893.
Chen, J., Bardes, E.E., Aronow, B.J., and Jegga, A.G. (2009). ToppGene Suite
for gene list enrichment analysis and candidate gene prioritization. Nucleic
Acids Res. 37, W305-11.
Cornwell, E.W., Mirbod, A., Wu, C.L., Kandarian, S.C., and Jackman, R.W.
(2014). C26 cancer-induced muscle wasting is IKKb-dependent and NF-kap-
paB-independent. PLoS ONE 9, e87776.
D’Orlando, C., Marzetti, E., Franc¸ois, S., Lorenzi, M., Conti, V., di Stasio, E.,
Rosa, F., Brunelli, S., Doglietto, G.B., Pacelli, F., and Bossola, M. (2014).
Gastric cancer does not affect the expression of atrophy-related genes in
human skeletal muscle. Muscle Nerve 49, 528–533.
Danai, L.V., Babic, A., Rosenthal, M.H., Dennstedt, E.A., Muir, A., Lien, E.C.,
Mayers, J.R., Tai, K., Lau, A.N., Jones-Sali, P., et al. (2018). Altered exocrine
function can drive adipose wasting in early pancreatic cancer. Nature 558,
600–604.
Delitto, D., Judge, S.M., Delitto, A.E., Nosacka, R.L., Rocha, F.G., DiVita, B.B.,
Gerber, M.H., George, T.J., Jr., Behrns, K.E., Hughes, S.J., et al. (2017). Hu-
man pancreatic cancer xenografts recapitulate key aspects of cancer
cachexia. Oncotarget 8, 1177–1189.
Dewys, W.D., Begg, C., Lavin, P.T., Band, P.R., Bennett, J.M., Bertino, J.R.,
Cohen, M.H., Douglass, H.O., Jr., Engstrom, P.F., Ezdinli, E.Z., et al.; Eastern
Cooperative Oncology Group (1980). Prognostic effect of weight loss prior to
chemotherapy in cancer patients. Am. J. Med. 69, 491–497.
Fearon, K., Strasser, F., Anker, S.D., Bosaeus, I., Bruera, E., Fainsinger, R.L.,
Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., et al. (2011). Definition
and classification of cancer cachexia: an international consensus. Lancet
Oncol. 12, 489–495.
Gades, N.M., Ohash, A., Mills, L.D., Rowley, M.A., Predmore, K.S., Marler,
R.J., and Couch, F.J. (2008). Spontaneous vulvar papillomas in a colony of
mice used for pancreatic cancer research. Comp. Med. 58, 271–275.
Gallagher, I.J., Stephens, N.A., MacDonald, A.J., Skipworth, R.J., Husi, H.,
Greig, C.A., Ross, J.A., Timmons, J.A., and Fearon, K.C. (2012). Suppression
of skeletal muscle turnover in cancer cachexia: evidence from the transcrip-
tome in sequential human muscle biopsies. Clin. Cancer Res. 18, 2817–2827.
1620 Cell Reports 28, 1612–1622, August 6, 2019
Go, K.L., Delitto, D., Judge, S.M., Gerber, M.H., George, T.J., Jr., Behrns, K.E.,
Hughes, S.J., Judge, A.R., and Trevino, J.G. (2017). Orthotopic Patient-
Derived Pancreatic Cancer Xenografts Engraft Into the Pancreatic Paren-
chyma, Metastasize, and Induce Muscle Wasting to Recapitulate the Human
Disease. Pancreas 46, 813–819.
Greco, S.H., Tomko¨tter, L., Vahle, A.K., Rokosh, R., Avanzi, A., Mahmood,
S.K., Deutsch, M., Alothman, S., Alqunaibit, D., Ochi, A., et al. (2015). TGF-b
Blockade Reduces Mortality and Metabolic Changes in a Validated Murine
Model of Pancreatic Cancer Cachexia. PLoS ONE 10, e0132786.
Guz, Y., Montminy, M.R., Stein, R., Leonard, J., Gamer, L.W.,Wright, C.V., and
Teitelman, G. (1995). Expression of murine STF-1, a putative insulin gene
transcription factor, in beta cells of pancreas, duodenal epithelium and
pancreatic exocrine and endocrine progenitors during ontogeny. Develop-
ment 121, 11–18.
He, W.A., Berardi, E., Cardillo, V.M., Acharyya, S., Aulino, P., Thomas-Ahner,
J.,Wang, J., Bloomston,M., Muscarella, P., Nau, P., et al. (2013). NF-kB-medi-
ated Pax7 dysregulation in the muscle microenvironment promotes cancer
cachexia. J. Clin. Invest. 123, 4821–4835.
Hingorani, S.R., Wang, L., Multani, A.S., Combs, C., Deramaudt, T.B., Hruban,
R.H., Rustgi, A.K., Chang, S., and Tuveson, D.A. (2005). Trp53R172H and
KrasG12D cooperate to promote chromosomal instability and widely metasta-
tic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469–483.
Hruban, R.H., Adsay, N.V., Albores-Saavedra, J., Anver, M.R., Biankin, A.V.,
Boivin, G.P., Furth, E.E., Furukawa, T., Klein, A., Klimstra, D.S., et al. (2006).
Pathology of genetically engineered mouse models of pancreatic exocrine
cancer: consensus report and recommendations. Cancer Res. 66, 95–106.
Jiang, K., Lawson, D., Cohen, C., and Siddiqui, M.T. (2014). Galectin-3 and
PTEN expression in pancreatic ductal adenocarcinoma, pancreatic neuroen-
docrine neoplasms and gastrointestinal tumors on fine-needle aspiration
cytology. Acta Cytol. 58, 281–287.
Judge, S.M., Wu, C.L., Beharry, A.W., Roberts, B.M., Ferreira, L.F., Kandarian,
S.C., and Judge, A.R. (2014). Genome-wide identification of FoxO-dependent
gene networks in skeletal muscle during C26 cancer cachexia. BMC Cancer
14, 997.
Kieler, M., Unseld, M., Bianconi, D., and Prager, G.W. (2017). Cross-over com-
parison and new chemotherapy regimens in metastatic pancreatic cancer.
Memo. 10, 136–140.
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., and Salzberg, S.L.
(2013). TopHat2: accurate alignment of transcriptomes in the presence of
insertions, deletions and gene fusions. Genome Biol. 14, R36.
Kim, D., Langmead, B., and Salzberg, S.L. (2015). HISAT: a fast spliced aligner
with low memory requirements. Nat. Methods 12, 357–360.
Lampson, B.L., Kendall, S.D., Ancrile, B.B., Morrison, M.M., Shealy, M.J., Bar-
rientos, K.S., Crowe, M.S., Kashatus, D.F., White, R.R., Gurley, S.B., et al.
(2012). Targeting eNOS in pancreatic cancer. Cancer Res. 72, 4472–4482.
Le-Rademacher, J.G., Crawford, J., Evans, W.J., and Jatoi, A. (2017). Over-
coming obstacles in the design of cancer anorexia/weight loss trials. Crit.
Rev. Oncol. Hematol. 117, 30–37.
Lerner, L., Hayes, T.G., Tao, N., Krieger, B., Feng, B., Wu, Z., Nicoletti, R.,
Chiu, M.I., Gyuris, J., and Garcia, J.M. (2015). Plasma growth differentiation
factor 15 is associated with weight loss and mortality in cancer patients.
J. Cachexia Sarcopenia Muscle 6, 317–324.
Lerner, L., Gyuris, J., Nicoletti, R., Gifford, J., Krieger, B., and Jatoi, A. (2016a).
Growth differentiating factor-15 (GDF-15): A potential biomarker and thera-
peutic target for cancer-associated weight loss. Oncol. Lett. 12, 4219–4223.
Lerner, L., Tao, J., Liu, Q., Nicoletti, R., Feng, B., Krieger, B., Mazsa, E., Siddi-
quee, Z., Wang, R., Huang, L., et al. (2016b). MAP3K11/GDF15 axis is a critical
driver of cancer cachexia. J. Cachexia Sarcopenia Muscle 7, 467–482.
Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general
purpose program for assigning sequence reads to genomic features. Bioinfor-
matics 30, 923–930.
Llovera, M., Garcı´a-Martı´nez, C., Lo´pez-Soriano, J., Agell, N., Lo´pez-Soriano,
F.J., Garcia, I., and Argile´s, J.M. (1998a). Protein turnover in skeletal muscle of
tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1.
Cancer Lett. 130, 19–27.
Llovera, M., Garcı´a-Martı´nez, C., Lo´pez-Soriano, J., Carbo´, N., Agell, N., Lo´-
pez-Soriano, F.J., and Argiles, J.M. (1998b). Role of TNF receptor 1 in protein
turnover during cancer cachexia using gene knockout mice. Mol. Cell. Endo-
crinol. 142, 183–189.
Madisen, L., Zwingman, T.A., Sunkin, S.M., Oh, S.W., Zariwala, H.A., Gu, H.,
Ng, L.L., Palmiter, R.D., Hawrylycz, M.J., Jones, A.R., et al. (2010). A robust
and high-throughput Cre reporting and characterization system for the whole
mouse brain. Nat. Neurosci. 13, 133–140.
Michaelis, K.A., Zhu, X., Burfeind, K.G., Krasnow, S.M., Levasseur, P.R., Mor-
gan, T.K., and Marks, D.L. (2017). Establishment and characterization of a
novel murine model of pancreatic cancer cachexia. J. Cachexia Sarcopenia
Muscle 8, 824–838.
Minnaard, R., Drost, M.R., Wagenmakers, A.J., van Kranenburg, G.P.,
Kuipers, H., and Hesselink, M.K. (2005). Skeletal Muscle wasting and contrac-
tile performance in septic rats. Muscle Nerve 31, 339–348.
Moningi, S., Walker, A.J., Hsu, C.C., Reese, J.B.,Wang, J.Y., Fan, K.Y., Rosati,
L.M., Laheru, D.A., Weiss, M.J., Wolfgang, C.L., et al. (2015). Correlation of
clinical stage and performance status with quality of life in patients seen in a
pancreas multidisciplinary clinic. J. Oncol. Pract. 11, e216–e221.
Nemer, L., Krishna, S.G., Shah, Z.K., Conwell, D.L., Cruz-Monserrate, Z., Dillh-
off, M., Guttridge, D.C., Hinton, A., Manilchuk, A., Pawlik, T.M., et al. (2017).
Predictors of Pancreatic Cancer-AssociatedWeight Loss and Nutritional Inter-
ventions. Pancreas 46, 1152–1157.
Pan, F.C., Bankaitis, E.D., Boyer, D., Xu, X., Van de Casteele, M., Magnuson,
M.A., Heimberg, H., and Wright, C.V. (2013). Spatiotemporal patterns of multi-
potentiality in Ptf1a-expressing cells during pancreas organogenesis and
injury-induced facultative restoration. Development 140, 751–764.
Parajuli, P., Kumar, S., Loumaye, A., Singh, P., Eragamreddy, S., Nguyen, T.L.,
Ozkan, S., Razzaque, M.S., Prunier, C., Thissen, J.P., and Atfi, A. (2018).
Twist1 Activation in Muscle Progenitor Cells Causes Muscle Loss Akin to Can-
cer Cachexia. Dev. Cell 45, 712–725.e6.
Pausch, T., Hartwig, W., Hinz, U., Swolana, T., Bundy, B.D., Hackert, T., Gre-
nacher, L., B€uchler, M.W., and Werner, J. (2012). Cachexia but not obesity
worsens the postoperative outcome after pancreatoduodenectomy in pancre-
atic cancer. Surgery 152 (3, Suppl 1), S81–S88.
Penna, F., Costamagna, D., Fanzani, A., Bonelli, G., Baccino, F.M., and Cost-
elli, P. (2010). Muscle wasting and impaired myogenesis in tumor bearing mice
are prevented by ERK inhibition. PLoS ONE 5, e13604.
Petruzzelli, M., Schweiger, M., Schreiber, R., Campos-Olivas, R., Tsoli, M., Al-
len, J., Swarbrick, M., Rose-John, S., Rincon, M., Robertson, G., et al. (2014).
A switch fromwhite to brown fat increases energy expenditure in cancer-asso-
ciated cachexia. Cell Metab. 20, 433–447.
Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K.
(2015). limma powers differential expression analyses for RNA-sequencing
and microarray studies. Nucleic Acids Res. 43, e47.
Roberts, B.M., Frye, G.S., Ahn, B., Ferreira, L.F., and Judge, A.R. (2013a). Can-
cer cachexia decreases specific force and accelerates fatigue in limb muscle.
Biochem. Biophys. Res. Commun. 435, 488–492.
Roberts, E.W., Deonarine, A., Jones, J.O., Denton, A.E., Feig, C., Lyons, S.K.,
Espeli, M., Kraman, M., McKenna, B., Wells, R.J., et al. (2013b). Depletion of
stromal cells expressing fibroblast activation protein-a from skeletal muscle
and bone marrow results in cachexia and anemia. J. Exp. Med. 210, 1137–
1151.
Segal, S.S., White, T.P., and Faulkner, J.A. (1986). Architecture, composition,
and contractile properties of rat soleus muscle grafts. Am. J. Physiol. 250,
C474–C479.
Shakya, R., Gonda, T., Quante, M., Salas, M., Kim, S., Brooks, J., Hirsch, S.,
Davies, J., Cullo, A., Olive, K., et al. (2013). Hypomethylating therapy in an
aggressive stroma-rich model of pancreatic carcinoma. Cancer Res. 73,
885–896.
Cell Reports 28, 1612–1622, August 6, 2019 1621
Stanger, B.Z., Stiles, B., Lauwers, G.Y., Bardeesy, N., Mendoza, M., Wang, Y.,
Greenwood, A., Cheng, K.H., McLaughlin, M., Brown, D., et al. (2005). Pten
constrains centroacinar cell expansion and malignant transformation in the
pancreas. Cancer Cell 8, 185–195.
Strassmann, G., Fong, M., Kenney, J.S., and Jacob, C.O. (1992). Evidence for
the involvement of interleukin 6 in experimental cancer cachexia. J. Clin.
Invest. 89, 1681–1684.
Talbert, E.E., Metzger, G.A., He, W.A., and Guttridge, D.C. (2014). Modeling
human cancer cachexia in colon 26 tumor-bearing adult mice. J. Cachexia
Sarcopenia Muscle 5, 321–328.
Talbert, E.E., Yang, J., Mace, T.A., Farren, M.R., Farris, A.B., Young, G.S., El-
naggar, O., Che, Z., Timmers, C.D., Rajasekera, P., et al. (2017). Dual Inhibition
of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic
and -Intrinsic Activities. Mol. Cancer Ther. 16, 344–356.
Talbert, E.E., Lewis, H.L., Farren, M.R., Ramsey,M.L., Chakedis, J.M., Rajase-
kera, P., Haverick, E., Sarna, A., Bloomston, M., Pawlik, T.M., et al. (2018).
Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with
cachexia in treatment-naı¨ve pancreatic cancer patients. J. Cachexia Sarcope-
nia Muscle 9, 358–368.
Tanaka, Y., Eda, H., Tanaka, T., Udagawa, T., Ishikawa, T., Horii, I., Ishitsuka,
H., Kataoka, T., and Taguchi, T. (1990). Experimental cancer cachexia induced
by transplantable colon 26 adenocarcinoma in mice. Cancer Res. 50, 2290–
2295.
Temel, J.S., Abernethy, A.P., Currow, D.C., Friend, J., Duus, E.M., Yan, Y., and
Fearon, K.C. (2016). Anamorelin in patients with non-small-cell lung cancer
and cachexia (ROMANA 1 and ROMANA 2): results from two randomised,
double-blind, phase 3 trials. Lancet Oncol. 17, 519–531.
Tisdale, M.J. (2009). Mechanisms of cancer cachexia. Physiol. Rev. 89,
381–410.
Toth, M.J., Miller, M.S., Callahan, D.M., Sweeny, A.P., Nunez, I., Grunberg,
S.M., Der-Torossian, H., Couch, M.E., and Dittus, K. (2013). Molecular mech-
anisms underlying skeletal muscle weakness in human cancer: reduced
myosin-actin cross-bridge formation and kinetics. J. Appl. Physiol. 114,
858–868.
Ullman-Cullere´, M.H., and Foltz, C.J. (1999). Body condition scoring: a rapid
and accurate method for assessing health status in mice. Lab. Anim. Sci.
49, 319–323.
von Haehling, S., Anker, M.S., and Anker, S.D. (2016). Prevalence and clinical
impact of cachexia in chronic illness in Europe, USA, and Japan: facts and
numbers update 2016. J. Cachexia Sarcopenia Muscle 7, 507–509.
Wang, L., Wang, S., and Li, W. (2012). RSeQC: quality control of RNA-seq
experiments. Bioinformatics 28, 2184–2185.
Weber, M.A., Krakowski-Roosen, H., Schro¨der, L., Kinscherf, R., Krix, M.,
Kopp-Schneider, A., Essig, M., Bachert, P., Kauczor, H.U., and Hildebrandt,
W. (2009). Morphology, metabolism, microcirculation, and strength of skeletal
muscles in cancer-related cachexia. Acta Oncol. 48, 116–124.
White, R.B., Bie´rinx, A.S., Gnocchi, V.F., and Zammit, P.S. (2010). Dynamics
of muscle fibre growth during postnatal mouse development. BMC Dev.
Biol. 10, 21.
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama,M., Hru-
ban, R.H., Eshleman, J.R., Nowak, M.A., et al. (2010). Distant metastasis
occurs late during the genetic evolution of pancreatic cancer. Nature 467,
1114–1117.
Yang, J., Zhang, Z., Zhang, Y., Ni, X., Zhang, G., Cui, X., Liu, M., Xu, C., Zhang,
Q., Zhu, H., et al. (2019). ZIP4 Promotes Muscle Wasting and Cachexia in Mice
With Orthotopic Pancreatic Tumors by Stimulating RAB27B-Regulated
Release of Extracellular Vesicles From Cancer Cells. Gastroenterology 156,
722–734.e6.
Ying, H., Elpek, K.G., Vinjamoori, A., Zimmerman, S.M., Chu, G.C., Yan, H.,
Fletcher-Sananikone, E., Zhang, H., Liu, Y., Wang, W., et al. (2011). PTEN is
a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates
an NF-kB-cytokine network. Cancer Discov. 1, 158–169.
Zhang, G., Liu, Z., Ding, H., Miao, H., Garcia, J.M., and Li, Y.P. (2017). Toll-like
receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coor-
dinate activation of protein degradation pathways. Sci. Rep. 7, 2273.
1622 Cell Reports 28, 1612–1622, August 6, 2019
STAR+METHODS
KEY RESOURCES TABLE
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Denis
Guttridge (guttridg@musc.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
All animal experiments were approved by the Ohio State University Institutional Animal Care and Use Committee under protocol
2010A00000177 or the Medical University of South Carolina Institutional Animal Care and Use Committee under protocol 2018-
00328. All animals were housed with littermates and given ad libitum access to standard chow and water. C-26 and LLC mice
were allocated to tumor-bearing and control groups randomly, genetic models were allocated by genotype.
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Ki67 Abcam ab16667; RRID: AB_302459
a-smooth muscle actin (a-SMA) Abcam ab5694; RRID: AB_2223021
cytokeratin 19 (CK19) Iowa Development Studies Hybridoma Bank TROMA-III; RRID: AB_2133570
laminin ThermoScientific MA1-06100; RRID: AB_559896
myosin heavy chain Type I Iowa Development Studies Hybridoma Bank A4.840; RRID: AB_528384
myosin heavy chain Type IIA Iowa Development Studies Hybridoma Bank sc-71; RRID: AB_2147165
Biological Samples
rectus abdominus muscle biopsies Pancreatic cancer patients and control patients
undergoing abdominal surgery
N/A
Deposited Data
Raw RNA-Seq files (human) This paper GEO: GSE133523
Raw RNA-Seq files (mouse) This paper GEO: GSE133524
Experimental Models: Cell Lines
Colon-26 (C-26) National Cancer Institute N/A
Lewis Lung Carcinoma (LLC) National Cancer Institute N/A
Experimental Models: Organisms/Strains
KrasLSL-G12D (KPP) The Jackson Laboratory #008179
Ptenf/f The Jackson Laboratory #006440
Ptf1aER-Cre The Jackson Laboratory #019378
Rosa26-tdTomato The Jackson Laboratory #007914
KrasLSL-G12D (KPC) NCI Frederick Mouse Repository 01XJ6
Pdx1Cre NCI Frederick Mouse Repository 01XL5
Trp53+/R270H NCI Frederick Mouse Repository 01XM3
Oligonucleotides
Primers for RT-PCR, see Table S7 This paper, Talbert et al., 2014 N/A
Software and Algorithms
tophat2 Kim et al., 2013 v2.1.0
HISAT2 Kim et al., 2015 v2.0.5
featureCounts Liao et al., 2014 v1.4.5
RSeQC Wang et al., 2012 v2.6.4
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C-26 Mice
Experiments using the colon-26 (C-26) model were conducted as previously described (He et al., 2013; Talbert et al., 2014; Tanaka
et al., 1990). Male CD2F1 mice from Charles River Laboratories were injected subcutaneously in the right flank with 1x106 C-26 cells
under anesthesia. Control mice received an injection the same volume of phosphate buffered saline. Mice were euthanized by CO2
asphyxiation 21 days after injection, at which time tumor-bearing mice had reached IACUC euthanasia criteria of tumor volume or
greater than 20% body weight loss.
LLC Mice
Experiments using the Lewis Lung Carcinoma (LLC) model were conducted as previously described (He et al., 2013; Llovera et al.,
1998a; Talbert et al., 2017). Male C57BL/6Jmice from Jackson Laboratories were injected intramuscularly in the right gluteusmuscle
with 5x105 LLC cells under anesthesia. Control mice received an injection the same volume of phosphate buffered saline. Mice were
euthanized by CO2 asphyxiation 21 days after injection, at which time tumor-bearing mice had reached IACUC euthanasia criteria of
tumor volume or > 20% weight loss.
KPC Mice
KPC mice (Kras+/LSL-G12D, Trp53+/R270H, Pdx1+/Cre) were provided by the Target Validation Shared Resource of The Ohio State
Comprehensive Cancer Center. Mice were maintained on a mixed background (Shakya et al., 2013). Mice were euthanized by
CO2 asphyxiation upon reaching IACUC-approved endpoint criteria, which included ascites, weight loss, lethargy, and severe
skin papillomas. Both male and female KPC mice were utilized, with same-sex littermates were used as controls.
KPP Mice
Alleles used to generate KPP mice were obtained from Jackson Laboratory on a C57BL/6J background. The initial cohort of KPP
mice was generated by breeding KrasLSL-G12D/+, Pten+/f mice to Ptf1aER-Cre/+, Pten+/f mice. Subsequent mice, including all mice
euthanized prior to reaching endpoint criteria, were generated by breeding KrasLSL-G12D/+, Ptenf/f mice to Ptf1aER-Cre/+, Ptenf/f
mice. Both male and female KPP mice were utilized, with same-sex littermates were used as controls. Genotypes of control mice
appear in Tables S4, S5, and S6.
KPP mice and littermate controls were treated with tamoxifen by five consecutive daily intraperitoneal injections. Mice
treated between 24-28 days of age received 1 mg tamoxifen/10 g of body weight, while year-old mice received 2 mg
tamoxifen/dose.
Endpoint KPP mice euthanized upon reaching IACUC endpoint criteria, which included ascites, weight loss, lethargy, and a body
condition score less than 1.5 (Ullman-Cullere´ and Foltz, 1999). Mice were euthanized at a surgical plane of isoflurane by cardiac
puncture followed by cervical dislocation. Final body weights were collected after the draining of ascites fluid. Absence of pancreas
pathology was confirmed in all mice utilized as controls by a veterinary pathologist.
Human Subjects
Patients undergoing attempted pancreatic resections at The Ohio State University Wexner Medical Center were asked to participate
in a tissue banking protocol under which rectus abdominus muscle biopsies taken during surgery were deposited into a tissue bank
run by The Ohio State University Comprehensive Cancer Center Pancreatic Cancer Program. Control muscle tissue was obtained
from consenting volunteers without malignancy who were undergoing laparotomy for elective indications (e.g., hernia repair, ostomy
reversal). All experiments were approved by The Ohio State University Cancer Institutional Review Board and all patients provided
informed consent.
Patients with greater than 5% loss of their pre-illness weight were classified as cachectic (Fearon et al., 2011). When possible, self-
reported weight loss was supported by a patient’s existingmedical record. All tissue samples used in this analysis were from patients
who had not received chemotherapy or radiation prior to surgery for this incidence of cancer. A previous history of a cancer was not
an exclusionary criterion. Clinical characteristics of the patients from which muscle was used for RNA-Seq are included in Table S2,
with characteristics of patients used for RT-PCR in Table S3. RNA-Seq was conducted onmuscle frommale subjects, while RT-PCR
was performed on a roughly even mix of male and female subjects.
METHOD DETAILS
RNA-Seq and Gene Ontology
RNA was isolated from snap-frozen tibialis anterior (mouse) or rectus abdominus (human) muscle using Trizol reagent (Life Tech-
nologies, Carlsbad, CA) according to the manufacturer’s instructions. RNA quality was assessed using an Agilent Bioanalyzer
RNA 6000 Nano chip and RIN numbers for all samples were greater than 7. rRNA was removed from purified total RNA using
Ribo-Zero Gold rRNA Removal kit (Illumina; MRZG12324). 200 ng of rRNA-depleted RNA was used for the construction of the
library using the SureSelect Strand Specific RNA library prep kit (Agilent; G9691A) according to the manufacturer’s instruction,
except for omitting the purification step before fragmentation. Barcoded libraries were pooled and sequenced using an Illumina
HiSeq4000.
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For muscle samples from mice, raw reads were aligned to Mus musculus GRCm38 from ensembl with tophat2v2.1.0 (Kim et al.,
2013) which ran with gene model annotations provided by GRCm38 v83. Sequence for samples frommultiple lanes were combined.
Alignment QC was generated with RSeQCv2.6.4 (Wang et al., 2012) and picardv2.4.1 (http://broadinstitute.github.io/picard). Frag-
ment counts were generated with featureCounts v1.4.5 (Liao et al., 2014) from the subread package for genes described by ensembl
GRCm38 v83. For reads with multiple alignments, the primary alignment was counted by featureCounts. Strand-specific read count-
ing was performed based on sequence that is reversely stranded. Differential expression was performed with limma (Ritchie et al.,
2015) for genes with CPM > 2 in 4 or more samples.
For muscle samples from patients, raw reads for human samples were aligned to Homo sapiensGRCh38 with HISAT2 v2.0.5 (Kim
et al., 2015). Alignment QC was generated with RSeQCv2.6.4 (Wang et al., 2012) and picardv2.4.1 (http://broadinstitute.github.io/
picard). Fragment counts were generated with featureCounts v1.4.5 (Liao et al., 2014) from the subread package for genes described
by ensembl GRCh38 v86. For reads with multiple alignments, the primary alignment was counted by featureCounts. Strand-specific
read counting was performed based on sequence that is reversely stranded. Differential expression was performed with limma
(Ritchie et al., 2015) for genes with CPM > 2 in more than half the samples. For human samples, gene downregulation confirmed
by real-time RT-PCR for 9 samples with RNA available. For both human and mouse samples, gene ontology was performed using
the ToppFun application of the ToppGene Suite (Chen et al., 2009). Heatmapswere producedwithMorpheus from the Broad Institute
(https://software.broadinstitute.org/morpheus).
Real-Time RT-PCR
Messenger RNA was isolated from snap-frozen quadriceps (mouse) or rectus abdominus (human) muscle using Trizol reagent (Life
Technologies, Carlsbad, CA) according to the manufacturer’s instructions. M-MLV Reverse Transcriptase (Life Technologies) was
used to reverse-transcribe total RNA to cDNA according to the manufacturer’s instructions. Real-time PCR was performed on an
Applied Biosystems StepOnePlus instrument using SYBR Green mix (Bio-Rad, Hercules, CA). GAPDH was used as the house-
keeping gene. Primer sequences appear in Table S7.
Pancreas Histopathology
Formalin-fixed, paraffin-embedded, hematoxylin-and-eosin-stained pancreata of KPC and KPPmice were assessed by a veterinary
pathologist employing recommended nomenclature for pancreatic exocrine neoplasia (Hruban et al., 2006). To better characterize
the lesions, pancreas sections from endpoint KPPmice were stained for Alcian blue to detect mucin and glycoproteins, Ki67 (1:200),
a-smooth muscle actin (a-SMA, 1:5000), and cytokeratin 19 (CK19, 1:500). The sections were imaged using a Vectra Multispectral
Imaging System (Perkin-Elmer).
CLAMS
Endpoint KPP mice (n = 5) were single-housed in a Comprehensive Lab Animal Monitoring System (CLAMS) unit (Columbus Instru-
ments, Columbus, OH) for 24 hours prior to euthanasia. Environmental temperature was held constant at 25 C. Mice were placed in
the unit at 10 AM, and daytime data were collected from 12PMuntil fiveminutes prior to lights out. Night data were collected from one
hour after lights out until 5 minutes prior to lights on.
Muscle Fiber Size Measurements
Muscle fiber cross-sectional area (CSA) of individual fiber types was determined from 10 mM sections of gastrocnemius stained for
laminin, myosin heavy chain Type IIA, and myosin heavy chain Type I by a modification of Minnaard (Minnaard et al., 2005). Muscle
fiber CSA was determined using a semi-automated ImageJ plug-in designed in the Guttridge lab which outlines the internal laminin
border of individual muscle fibers and then assigns fiber types based upon color of the fiber.
Muscle Function Measurements
Extensor digitorum longus (EDL) force production was measured across a force-frequency curve. Force was normalized to CSA as
previously described (Segal et al., 1986).
Sarcomeric Protein Analysis
Muscle sarcomere components were analyzed as previously described (Blough et al., 1996).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was conducted with GraphPad Prism 7, and the details of these analyses appear in the figure legends with
samples per group (n). Unless otherwise noted, data are presented as mean ± the standard error of the mean (SEM). For KPC
and KPP mice, comparisons between groups were made by two-tailed paired t tests. For C-26 and LLC mice and comparisons
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between human subjects, unpaired two-tailed tests were used. Statistical analysis of tissue masses was conducted on absolute
values, regardless of the presentation of the data. Statistical significance was defined a priori as p < 0.05.
DATA AND CODE AVAILABILITY
Raw RNA-Seq data files are available in the NCBI’s GEO: GSE133523 and GSE133524.
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